Dupixent (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Media coverage

• Title	Dupixent (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
  Media name/outlet	Market News Publishing
  Country/Territory	United States
  Date	23/10/23
  Persons	Mirna Chehade

• Title	Dupixent (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
  Media name/outlet	Market News Publishing
  Country/Territory	United States
  Date	23/10/23
  Persons	Mirna Chehade